Table 1.
Baseline Characteristics
| Placebo (n = 151) | Darapladib (n = 172) | |
|---|---|---|
| Clinical characteristics | ||
| Age (y) | 57.3 ± 10.9 | 59.4 ± 9.8 |
| Males (n, %) | 126 (83) | 140 (81) |
| Body-mass index (kg/m2) | 27.8 ± 3.8 | 27.5 ± 4.0 |
| Diabetes mellitus (n, %) | 22 (15) | 22 (13) |
| Hypertension (n, %) | 89 (59) | 115 (67) |
| Low HDL cholesterol (<40 mg/dL) (n, %) | 40 (26) | 45 (26) |
| Hypercholesterolemia (n, %) | 95 (63) | 108 (63) |
| Current smoker (n, %) | ||
| Prior medical history (n, %) | 57 (38) | 64 (37) |
| Prior myocardial infarction | 49 (32) | 51 (29) |
| Prior coronary revascularization | 47 (31) | 50 (29) |
| Peripheral artery disease | 7 (5) | 17 (10) |
| Prior stroke | 3 (2) | 4 (2) |
| Index hospitalization (n, %) | ||
| ACS | 74 (49) | 87 (51) |
| STEMI | 35 (23) | 40 (23) |
| Non-STEMI | 39 (26) | 47 (27) |
| PCI during index hospitalization | 122 (81) | 130 (76) |
| Cardiovascular medications at randomization (n, %) | ||
| Aspirin | 138 (91) | 149 (87) |
| Clopidogrel or ticlopidine | 122 (81) | 136 (79) |
| Any antiplatelet medication | 150 (> 99) | 170 (99) |
| ACE inhibitors or ARBs | 88 (58) | 101 (59) |
| Beta-blockers | 119 (79) | 138 (80) |
| Statins | 134 (89) | 157 (91) |
| Laboratory values | ||
| Cholesterol (mg/dL) | ||
| Total | 187.3 ± 47.6 | 182.3 ± 43.2 |
| LDL | 108.2 ± 41.4 | 103.6 ± 37.4 |
| HDL | 46.8 ± 11.2 | 48.0 ± 12.4 |
| Triglycerides (mg/dL) | ||
| Median | 141 | 136 |
| IQR | 97–202 | 96–193 |
| hsC-reactive protein (mg/L) | ||
| geometric mean | 2.4 | 2.4 |
| 95% CI | 1.9, 3.1 | 1.9, 3.0 |
| Lp-PLA2 activity (μmol/min/L) | ||
| geometric mean | 159 | 160 |
| 95% CI | 152, 167 | 153, 167 |
| Blood pressure | ||
| Systolic (mm Hg) | 125.7 ± 16.9 | 128.0 ± 16.1 |
| Diastolic (mmHg) | 75.2 ± 10.1 | 75.6 ± 9.9 |
| Study vessela–no. (%) | ||
| LAD | 44 (36) | 56 (39) |
| LCX | 32 (26) | 37 (26) |
| RCA | 45 (37) | 51 (35) |
| Diameter stenosisb (%) | 28.0 (10.5) | 26.6 (10.3) |
| Mean lumen diameterb (mm) | 2.9 ± 0.5 | 3.0 ± 0.6 |
Values are presented as mean ± SD unless otherwise specified; To convert to mmol/L multiply values of cholesterol by 0.02586 and triglycerides by 0.0113
PCI percutaneous coronary intervention, ACS acute coronary syndromes
aImaging evaluable population: placebo 121 patients; darapladib 146 patients
bQuantitative coronary angiography: placebo 121 patients; darapladib 144 patients